Page Metadata

CLINUVEL PHARMACEUTICALS LTD

Company Profile

Clinuvel Pharmaceuticals Ltd. is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million.

CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation by the European Commission for adults with EPP. Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.

Summary

$5.88
$5.97
5,641
$5.88 - $5.91
4.10 %
$5.91
$5.88
8,604
1:1
$281.6M
--
--

Corporate Information

Executive Team
Dr. Philippe Wolgen, Managing Director and Chief Executive Offer. Non-voting member of the Audit and Risk Committee and the Remuneration
Dr. Dennis Wright, Acting Chief Scientific Officer
Mr. Darren Keamy, Chief Financial Officer, Company Secretary
ADR Bank: BNY Mellon
Company IR Website
Nasdaq International Designation, June 2, 2016

Clinuvel

REGISTERED OFFICE ADDRESS
Level 6, 15 Queen Street, AUSTRALIA, 3000
HEAD OFFICE TELEPHONE
GICS INDUSTRY GROUP
Biotechnology

Resources


Company Photos

Clinuvel Pharmaceuticals LTD

Clinuvel Tower Image NID
Clinuvel Pharmaceuticals LTD in NYC's Times Square Promotion of Clinuvel's membership in the Nasdaq International Designation program on Nasdaq Tower in Times Square
Clinuvel Logo Image
Clinuvel Pharmaceuticals ltd's Products Learn more about Clinuvel's products.


Social

Scroll up